Neovacs S.A Current ratio
What is the Current ratio of Neovacs S.A?
The Current ratio of Neovacs S.A. is 2.16
What is the definition of Current ratio?
Current ratio is a liquidity ratio that measures whether or not a company has enough resources to meet its short-term obligations.
mrq (most recent quarter)
The current ratio is an indication of a company's liquidity and measures the capability to meet a company's short-term obligations. It compares a firm's current assets to its current liabilities, and is expressed as current assets divided by current liabilities. The ratio is only useful when two companies are compared within industry because inter industry business operations differ substantially. To determine liquidity, the current ratio is not as helpful as the quick ratio, because it includes all those assets that may not be easily liquidated, like prepaid expenses and inventory.
Acceptable current ratios vary from industry to industry. In many cases an investor would consider a high current ratio to be better than a low current ratio, because a high current ratio indicates that the company is more likely to pay the investor back. Large current ratios are not always a good sign for investors. If the company's current ratio is too high it may indicate that the company is not efficiently using its current assets or its short-term financing facilities. If current liabilities exceed current assets the current ratio will be less than 1. A current ratio of less than 1 indicates that the company may have problems meeting its short-term obligations.
Some types of businesses can operate with a current ratio of less than one however. If inventory turns into cash much more rapidly than the accounts payable become due, then the firm's current ratio can comfortably remain less than one. Inventory is valued at the cost of acquiring it and the firm intends to sell the inventory for more than this cost. The sale will therefore generate substantially more cash than the value of inventory on the balance sheet. Low current ratios can also be justified for businesses that can collect cash from customers long before they need to pay their suppliers.
Current ratio of companies in the Health Care sector on EURONEXT compared to Neovacs S.A
What does Neovacs S.A do?
Neovacs S.A., a biotechnology company, focuses on the development of therapeutic vaccines for the treatment of autoimmune, inflammatory, allergy, and cancer diseases in France. It develops treatments for chronic autoimmune and inflammatory diseases using its proprietary Kinoid technology. The company's product pipeline includes IFNa Kinoid, an anti-interferon alpha vaccine that is in Phase IIb clinical trial for the treatment of systemic lupus erythematosus; Phase IIa clinical trial for the treatment of dermatomyositis; and preclinical stage for the treatment of diabetes. It is also developing VEGF-Kinoid, which is in preclinical stage for the treatment of age-related macular degeneration and solid tumors; and IL-4/IL-13 Kinoid that is in preclinical stage for the treatment of allergies. The company has a collaboration with the Sunnybrook Research Institute for preclinical development of VEGF Kinoid to treat colorectal and ovarian cancer. Neovacs S.A. was founded in 1993 and is based in Paris, France.
Companies with current ratio similar to Neovacs S.A
- Juva Life has Current ratio of 2.16
- Thunder Gold Corp has Current ratio of 2.16
- White Metal Resources has Current ratio of 2.16
- GetBack S.A has Current ratio of 2.16
- Pangaea Logistics Solutions Ltd has Current ratio of 2.16
- Sanibel Ventures has Current ratio of 2.16
- Neovacs S.A has Current ratio of 2.16
- Castrol India has Current ratio of 2.16
- Bufab AB (publ) has Current ratio of 2.16
- Blue Thunder Mining has Current ratio of 2.16
- Domtar has Current ratio of 2.16
- Eagle Pharmaceuticals Inc has Current ratio of 2.16
- Namoi Cotton has Current ratio of 2.16